TRACK-FA Study

Friedreich ataxia (FA) is an inherited, multisystem neurodegenerative disease that results in profound changes to speech, swallowing, balance, walking, cardiac health and upper limb function.

TRACK-FA is an imaging study focussed on building a better understanding of the impact FA has on the brain and its relationship to clinical features of the disease. The team of investigators working across 7 sites in the USA, Brazil, Australia, Germany and Canada scan patients every 12 months over 3 years using sophisticated brain imaging techniques. Patients are also completing a comprehensive battery of clinical assessments to establish the relationship between the brain and behaviour.

Redenlab are supporting the study through the inclusion of a digital speech protocol. Data will inform future protocol design in ataxia and strengthen links between meaningful clinical outcomes and underlying neuropathology.

For more information on the protocol and the team at Monash leading the study, click here.

Related Post

  • Posted on 11 December, 2024
    MEDIA RELEASE Melbourne - December 2024 – Redenlab, a leader in innovative healthcare solutions, has partnered with the Queensland Institute of Medical...
    • Posted on 12 November, 2024
      Redenlab is excited to announce that Prof. Adam Vogel will be speaking at the upcoming International Congress for Ataxia Research...
      • Posted on 31 March, 2024
        Speech and language impairments are core features of the neurodevelopmental genetic condition Kleefstra syndrome. The speech, language and cognitive profile...